Arcutis Biotherapeutics (ARQT) vs Xenon Pharmaceuticals (XENE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Arcutis Biotherapeutics (ARQT) has outperformed Xenon Pharmaceuticals (XENE) over the past year, gaining 28.3% versus a loss of 11.7%. Over five years, ARQT leads with a +19.3% price change compared with +7.4% for XENE. Xenon Pharmaceuticals is the larger company by market cap ($3.53 billion vs $3.34 billion), about 1.1 times the size.
Arcutis Biotherapeutics converts more of its revenue into profit, with a net margin of -4.3% versus -4612.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARQT | XENE |
|---|---|---|
| Share price | $26.58 | $36.44 |
| Market cap | $3.34B | $3.53B |
| 1-day change | +8.53% | +0.77% |
| YTD return | -8.47% | -18.70% |
| 1-year return | +28.34% | -11.72% |
| 5-year return | +19.30% | +7.43% |
| P/E ratio (TTM) | 120.82 | — |
| Forward P/E | 19.54 | — |
| EPS (TTM) | $0.22 | $-4.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $376.07M | $7.50M |
| Revenue growth (YoY) | +91.34% | — |
| Net income (latest FY) | $-16.14M | $-345.91M |
| Gross margin | 90.24% | — |
| Operating margin | -3.25% | -4974.27% |
| Net margin | -4.29% | -4612.13% |
| 52-week high | $31.77 | $72.66 |
| 52-week low | $19.30 | $35.06 |
| Distance from 52-week high | -16.34% | -49.85% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +39.20% | +101.34% |
| Average volume | 2.23M | 1.42M |
| Shares outstanding | 125.69M | 96.84M |
| Employees | 354 | 358 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARQT has outperformed XENE by 40.1 percentage points over the past year.
- Arcutis Biotherapeutics is more profitable, keeping -4.3 cents of every revenue dollar as net income versus -4612.1 cents for Xenon Pharmaceuticals.
About Arcutis Biotherapeutics
ARQT stock →Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 354 employees
About Xenon Pharmaceuticals
XENE stock →Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression.
Health Care · Biotechnology: Pharmaceutical Preparations · 358 employees
ARQT vs XENE FAQ
Which is bigger, Arcutis Biotherapeutics or Xenon Pharmaceuticals?
Xenon Pharmaceuticals (XENE) is larger, with a market capitalization of $3.53B compared with $3.34B for Arcutis Biotherapeutics (ARQT).
Which stock has performed better over the past year, ARQT or XENE?
ARQT returned +28.34% over the past 12 months, compared with -11.72% for XENE (price return, excluding dividends). Past performance does not predict future results.
Are Arcutis Biotherapeutics and Xenon Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.